CredoScientia - Bibliothèque

[Conversion surgery strategy for adenocarcinoma of the esophagogastric junction].

The incidence of adenocarcinoma of the esophagogastric junction (AEG) continues to rise, with 20%-30% of patients initially diagnosed with stage IV disease, for whom conventional palliative treatment …

Thérapies de Conversion

Hu, W. Q., Peng, W., & Song, D. Y. (2026). [Conversion surgery strategy for adenocarcinoma of the esophagogastric junction].. Zhonghua Wei Chang Wai Ke Za Zhi, 29(5), 608-614. https://doi.org/10.3760/cma.j.cn441530-20260228-00101

25/05/2026 Lire →

[Innovation in the treatment paradigm for advanced-stage colorectal cancer: new strategies and future directions].

The treatment model for colorectal cancer has undergone a significant evolution, progressing from single surgical resection to multidisciplinary team (MDT)-based comprehensive therapy. As a revolution…

Thérapies de Conversion

Wei, J. S., Hu, H. G., Wang, J., & Ding, K. F. (2026). [Innovation in the treatment paradigm for advanced-stage colorectal cancer: new strategies and future directions].. Zhonghua Wei Chang Wai Ke Za Zhi, 29(5), 601-607. https://doi.org/10.3760/cma.j.cn441530-20260212-00085

25/05/2026 Lire →

[Expert consensus on the clinical application of the Chinese-modified triplet combination with irinotecan, oxaliplatin and continuous infusional 5-fluorouracil / leucovorin for colorectal cancer (2026 edition)].

Chemotherapy is the cornerstone of colorectal cancer treatment, especially for microsatellite stable/proficient mismatch repair (MSS/pMMR) colorectal cancer. The FOLFOXIRI triplet regimen (fluorouraci…

Thérapies de Conversion

Committee, o. f. . C. o. l. o. r. e. c. t. a. l. . C. a. n. c. e. r. ,. . C. h. i. n. a. . S. o. u. t. h. w. e. s. t. . O. n. c. o. l. o. g. y. . G. r. o. u. p. (2026). [Expert consensus on the clinical application of the Chinese-modified triplet combination with irinotecan, oxaliplatin and continuous infusional 5-fluorouracil / leucovorin for colorectal cancer (2026 edition)].. Zhonghua Wei Chang Wai Ke Za Zhi, 29(5), 573-584. https://doi.org/10.3760/cma.j.cn441530-20260227-00099

25/05/2026 Lire →

[Chinese expert consensus on the management of immune-related adverse events associated with perioperative immunotherapy for gastrointestinal tumors (2026 edition)].

In recent years,immunotherapy has made breakthrough progress in the perioperative treatment of gastrointestinal tumors. Immunotherapy could improve pathologic response rates and long-term survival,but…

Thérapies de Conversion

Committee, f. o. r. . S. u. r. g. i. c. a. l. . S. a. f. e. t. y. . a. n. d. . Q. u. a. l. i. t. y. . C. o. n. t. r. o. l. ,. C. h. i. n. e. s. e. . A. n. t. i. -. C. a. n. c. e. r. . A. s. s. o. c. i. a. t. i. o. n. (2026). [Chinese expert consensus on the management of immune-related adverse events associated with perioperative immunotherapy for gastrointestinal tumors (2026 edition)].. Zhonghua Wei Chang Wai Ke Za Zhi, 29(5), 545-562. https://doi.org/10.3760/cma.j.cn441530-20260307-00114

25/05/2026 Lire →

Conversion therapy with arterial reconstruction: Redefining the resect-ability of locally advanced pancreatic cancer.

Thérapies de Conversion

Wang, F. F., Zhou, L., Dai, X. D., Liu, Q. P., Pan, B., Lang, R., He, Q., & Lyu, S. C. (2026). Conversion therapy with arterial reconstruction: Redefining the resect-ability of locally advanced pancreatic cancer.. Hepatobiliary Pancreat Dis Int. https://doi.org/10.1016/j.hbpd.2026.05.001

11/05/2026 Lire →

ASO Author Reflections: Radical Resection for HCC with PVTT After Second-Line Conversion Therapy.

Thérapies de Conversion

Tan, W., Wei, J., Luo, X., Zhong, J., Zhou, R., Chen, Y., & Shang, C. (2026). ASO Author Reflections: Radical Resection for HCC with PVTT After Second-Line Conversion Therapy.. Ann Surg Oncol. https://doi.org/10.1245/s10434-026-19784-x

11/05/2026 Lire →

Sintilimab (PD-1 inhibitor) plus lenvatinib as conversion therapy followed by sequential surgery (SILENSES) for advanced unresectable hepatocellular carcinoma: a phase II, expansion trial.

Our previous findings demonstrated the promising antitumor activity and manageable safety of sintilimab-lenvatinib conversion therapy. The current study aimed to evaluate long-term survival outcomes i…

Thérapies de Conversion

Lu, S., Zhang, W., Li, J., Zhang, Z., Hu, B., Li, X., Cao, Y., Wang, Z., Wang, Z., Ye, H., Qu, B., Li, Y., Ma, G., Wan, T., Liu, Z., Liu, B., Xu, Y., Tang, H., Zhao, X., … Bian, X. (2026). Sintilimab (PD-1 inhibitor) plus lenvatinib as conversion therapy followed by sequential surgery (SILENSES) for advanced unresectable hepatocellular carcinoma: a phase II, expansion trial.. Signal Transduct Target Ther, 11(1). https://doi.org/10.1038/s41392-026-02708-2

06/05/2026 Lire →

A Step Backward Regarding Conversion Therapy for LGBTQ+ Youth.

Thérapies de Conversion

Thomas, S. P. (2026). A Step Backward Regarding Conversion Therapy for LGBTQ+ Youth.. Issues Ment Health Nurs, 47(5), 427-428. https://doi.org/10.1080/01612840.2026.2662202

01/05/2026 Lire →

Pathological Complete Response in Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Following Conversion Therapy With TACE, HAIC, Lenvatinib, and Sintilimab: A Case Report.

Hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) is an advanced disease with poor prognosis and limited treatment options. Conversion therapy integrating locoregional and systemic…

Thérapies de Conversion

Zhang, W., Shen, H., Wang, X., Gu, J., Shen, M., & Zhang, Q. (2026). Pathological Complete Response in Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Following Conversion Therapy With TACE, HAIC, Lenvatinib, and Sintilimab: A Case Report.. Clin Case Rep, 14, e72711. https://doi.org/10.1002/ccr3.72711

01/05/2026 Lire →

Borderline Resectable Classification Identifies Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab.

BACKGROUND: Conversion therapy, which seeks to achieve curative treatment following systemic therapy, is increasingly acknowledged in the management of unresectable hepatocellular carcinoma (HCC). How…

Thérapies de Conversion

Takeuchi, Y., Sue, M., Miyake, N., Adachi, T., Onishi, H., Kawanaka, M., Takaki, A., Nouso, K., Kariyama, K., Nakamura, S., Tanaka, E., Tada, T., Yasunaka, T., Kuwaki, K., Toshimori, J., Iwado, S., Moriya, A., Hagihara, H., Takabatake, H., … Otsuka, M. (2026). Borderline Resectable Classification Identifies Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab.. Hepatol Res, 56(5), 830-839. https://doi.org/10.1111/hepr.70138

01/05/2026 Lire →

Conversion Therapy Based on TACE/HAIC-Based Treatment to Improve the Therapeutic Effect of Initially Unresectable Hepatocellular Carcinoma.

OBJECTIVES: The main objectives of this research are to evaluate the outcomes of patients with initially unresectable hepatocellular carcinoma (HCC) who received transcatheter arterial chemoembolizati…

Thérapies de Conversion

Lin, S., Song, Z., Chen, P., Yu, X., Xie, W., Hua, Y., Li, S., Shen, S., & Kuang, M. (2026). Conversion Therapy Based on TACE/HAIC-Based Treatment to Improve the Therapeutic Effect of Initially Unresectable Hepatocellular Carcinoma.. Liver Cancer, 15(2), 254-284. https://doi.org/10.1159/000547725

01/05/2026 Lire →

PD-1 inhibitors combined with tyrosine kinase inhibitors for conversion therapy in patients with unresectable hepatocellular carcinoma: a retrospective cohort study.

BACKGROUND: The majority of patients with hepatocellular carcinoma (HCC) are diagnosed at an advanced stage, precluding surgical resection. Studies have evaluated the use of programmed cell death prot…

Thérapies de Conversion

Liu, G., Guo, C., Li, X., Lv, Z., Du, J., & Gong, L. (2026). PD-1 inhibitors combined with tyrosine kinase inhibitors for conversion therapy in patients with unresectable hepatocellular carcinoma: a retrospective cohort study.. J Gastrointest Oncol, 17(2), 76. https://doi.org/10.21037/jgo-2026-1-0023

30/04/2026 Lire →